TAK 029

Known as: TAK-029 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1996-2008
012319962008

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Shear-induced platelet activation (SIPA) has been identified to induce platelet adhesion and thrombus formation in continuous… (More)
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2003
2003
This is the first laboratory evaluation of a new instrument, designed to test both platelet function and thrombolytic activity… (More)
Is this relevant?
2001
2001
Employing video-enhanced contrast (VEC) microscopy, we examined whether TAK-029 (GPIIb/IIIa antagonist) inhibits the adhesion of… (More)
Is this relevant?
2001
2001
To improve the in vitro and in vivo potency of our first low molecular weight GPIIb/IIIa antagonist 1 (TAK-029), a series of 2-[4… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 3
Is this relevant?
1998
1998
Previous studies have indicated that exposure of fibrinogen receptors associated with the glycoprotein IIb/IIIa complex… (More)
Is this relevant?
1998
1998
Based on the lead tetrapeptide RGDF, two possible non-peptide glycoprotein (GP) IIb-IIIa antagonists possessing an (S)-2… (More)
Is this relevant?
Review
1998
Review
1998
Monolithic microcapsules were designed and developed for controlled release of leuprorelin for one month following a single… (More)
Is this relevant?
1997
1997
The antithrombotic and bleeding time (BT) prolonging effects of TAK-029, a novel GPIIb/IIIa antagonist, were examined in three… (More)
Is this relevant?
1997
1997
Purpose. We prepared injectable microspheres for controlled release of TAK-029, a water-soluble GPIIb/IIIa antagonist and… (More)
Is this relevant?
1996
1996
The antithrombotic and bleeding time (BT)-prolonging effects of TAK-029, a novel glycoprotein IIb/IIIa antagonist, were… (More)
Is this relevant?